Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 223Carboplatin 219Cisplatin 206Paclitaxel 182Gemcitabine 149Docetaxel 127Capecitabine 115Pemetrexed 102Dexamethasone 102Cyclophosphamide 102Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 96Radiotherapy 95Doxorubicin 92Fluorouracil 88Bevacizumab 84Nivolumab 74Leucovorin 73Rituximab 71Vincristine 68durvalumab 66Lenalidomide 64Radiation 62Etoposide 62atezolizumab 61Irinotecan 61130-nm albumin-bound paclitaxel 58Prednisone 57Letrozole 55

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × afuresertib × 1 year × Clear all
NCT04851613 2026-04-02

Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer

Laekna Limited

Phase 3 Active not recruiting
256 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡